Overview

 
Home
 
Overview
 
Programme/Posters
 
Speakers/Abstracts
 
Presentations
 
Sponsors
 
Symposium Pictures
 
Symposium Report
 
Kinase Links
 
Meetings
 
Speakers Articles
 
 
 
The meeting is partially prompted by the fact that 2006 will see the 20th anniversary of the start of tyrosine kinase inhibitor research in Basel. This event ultimately led to the development of the first protein kinase therapeutic, Glivec. The symposium will focus on the impact of basic research on drug discovery and the impact that it is now having on treatment of cancer. We also wish to focus on contemporary issues in the protein kinase field, surveying the current landscape in terms of the development of targeted kinase inhibitors for cancer, and other areas. We hope to bring together basic researchers, chemists, pharmacologists, clinicians and the major contributors from the pharma industry.

We look forward very much to your participation.
Organizers:
- Dr Brian A. Hemmings, FMI, Basel
- Prof. Paul Herrling, Corporate Research, Novartis, Basel
- Dr. Myoung-Ok Kwon, Corporate Research, Novartis, Basel
Scientific committee:
- Prof. Max M. Burger, Novartis Science Board, Basel
- Dr Brian A. Hemmings, FMI, Basel
- Prof. Paul Herrling, Corporate Research, Novartis, Basel
- Prof. Bill Sellers, NIBR, Boston
Conference logistics :
Isabella Bogdal,
Phone: +41-61-6976653
Fax: +41-61-6973976
[email protected]
Thibaut Siegmann,
Phone: +41-61-6975187
Fax: +41-61-6973976
[email protected]
Nadine Streich,
Phone: +41 61 324 6009
Fax: +41 61 324 2522
[email protected]
Sponsors:
- Prof. Mark Fishman, President of the Novartis Institutes for BioMedical Research, Boston
- Prof. Susan Gasser, Director of the Friedrich Miescher Institute for Medical Research, Basel
- Prof. Paul Herrling, Head of Corporate Research, Novartis, Basel